TY - JOUR
T1 - Clinical Characteristics and Treatment Response in Microscopic Colitis Based on Age at Diagnosis
T2 - A Multicenter Retrospective Study
AU - Kamboj, Amrit K.
AU - McGoldrick, Jessica
AU - Voth, Eli
AU - Penrice, Daniel
AU - Tome, June
AU - Gujral, Amandeep
AU - Miller, Kaia
AU - Burke, Kristin E.
AU - Pardi, Darrell S.
AU - Khalili, Hamed
N1 - Funding Information:
DSP has consulted for Otsuka, Janssen, Merck, Casdin Capital, Salix, Nestle, C3 Jian, Seres Therapeutics, Assembly Bioscience, and has received research support from Seres Therapeutics, Atlantic, Takeda, Salix, Merck, and Pfizer. HK has consulted for AbbVie and receives grant funding from Takeda and Pfizer. HK is also funded by American College of Gastroenterology Clinical Research Award, the Crohn’s and Colitis Foundation Senior Research Award, the Becker Foundation, and the National Institute of Health (NIH) – R01 AG068390.
Funding Information:
DSP has consulted for Otsuka, Janssen, Merck, Casdin Capital, Salix, Nestle, C3 Jian, Seres Therapeutics, Assembly Bioscience, and has received research support from Seres Therapeutics, Atlantic, Takeda, Salix, Merck, and Pfizer. HK has consulted for AbbVie and receives grant funding from Takeda and Pfizer. HK is also funded by American College of Gastroenterology Clinical Research Award, the Crohn’s and Colitis Foundation Senior Research Award, the Becker Foundation, and the National Institute of Health (NIH) – R01 AG068390.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/7
Y1 - 2022/7
N2 - Background: Microscopic colitis (MC) primarily affects older adults; thus, data in younger patients are scarce. Aims: To compare clinical characteristics and treatment response by age at diagnosis. Methods: This retrospective cohort study was performed at Mayo Clinic and Massachusetts General Hospital. Patients were chosen consecutively using established databases. Patients were ‘younger’ if age at diagnosis was ≤ 50 years and ‘older’ if age > 50 years. Treatment outcomes were captured for induction (12 ± 4 weeks), based on the total number of daily stools, and defined as remission (complete resolution), response (≥ 50% improvement), non-response (< 50% improvement), and intolerance. Patients were considered ‘responders’ if they had remission or response and ‘non-responders’ if they had non-response or intolerance. Results: We included 295 patients (52 younger, 243 older). There were no differences in sex, race, MC subtype, and diarrhea severity between groups (all P > 0.05). Younger patients were more likely to have celiac disease (17.3% vs. 5.8%, P = 0.01), while older patients had higher BMI (mean 25.0 vs. 23.8 kg/m2, P = 0.04) were more likely smokers (53.9% vs. 34.6%, P = 0.01) and use NSAIDs (48.6% vs. 15.4%, P < 0.01) and statins (22.6% vs. 3.8%, P < 0.01). Overall treatment response was highest for budesonide (88.3%) and did not differ when comparing older to younger patients (90.6% vs. 77.8%, P = 0.12) or by MC subtype (LC, 81.5% vs. CC, 92.9%, P = 0.07). Conclusions: There are no significant differences in MC treatment response based on age or disease subtype. These findings support treating patients with MC based on symptom severity rather than age.
AB - Background: Microscopic colitis (MC) primarily affects older adults; thus, data in younger patients are scarce. Aims: To compare clinical characteristics and treatment response by age at diagnosis. Methods: This retrospective cohort study was performed at Mayo Clinic and Massachusetts General Hospital. Patients were chosen consecutively using established databases. Patients were ‘younger’ if age at diagnosis was ≤ 50 years and ‘older’ if age > 50 years. Treatment outcomes were captured for induction (12 ± 4 weeks), based on the total number of daily stools, and defined as remission (complete resolution), response (≥ 50% improvement), non-response (< 50% improvement), and intolerance. Patients were considered ‘responders’ if they had remission or response and ‘non-responders’ if they had non-response or intolerance. Results: We included 295 patients (52 younger, 243 older). There were no differences in sex, race, MC subtype, and diarrhea severity between groups (all P > 0.05). Younger patients were more likely to have celiac disease (17.3% vs. 5.8%, P = 0.01), while older patients had higher BMI (mean 25.0 vs. 23.8 kg/m2, P = 0.04) were more likely smokers (53.9% vs. 34.6%, P = 0.01) and use NSAIDs (48.6% vs. 15.4%, P < 0.01) and statins (22.6% vs. 3.8%, P < 0.01). Overall treatment response was highest for budesonide (88.3%) and did not differ when comparing older to younger patients (90.6% vs. 77.8%, P = 0.12) or by MC subtype (LC, 81.5% vs. CC, 92.9%, P = 0.07). Conclusions: There are no significant differences in MC treatment response based on age or disease subtype. These findings support treating patients with MC based on symptom severity rather than age.
KW - Bismuth subsalicylate
KW - Budesonide
KW - Collagenous colitis
KW - Diarrhea
KW - Loperamide
KW - Lymphocytic colitis
KW - Mesalamine
KW - Microscopic colitis
UR - http://www.scopus.com/inward/record.url?scp=85110856605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110856605&partnerID=8YFLogxK
U2 - 10.1007/s10620-021-07162-4
DO - 10.1007/s10620-021-07162-4
M3 - Article
C2 - 34283360
AN - SCOPUS:85110856605
SN - 0163-2116
VL - 67
SP - 3108
EP - 3114
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 7
ER -